相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
Lin Liu et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2020)
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial
Wen-Huan Feng et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2019)
Association of salivary levels of immunoglobulin-a and amylase with oral-dental manifestations in patients with controlled and non-controlled type 2 diabetes
Marjan Kheirmand Parizi et al.
BMC ORAL HEALTH (2019)
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Jinhua Yan et al.
HEPATOLOGY (2019)
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review
Ian Blazina et al.
SYSTEMATIC REVIEWS (2019)
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)
Laura Iogna Prat et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2018)
Downregulation of IL-22 can be considered as a risk factor for onset of type 2 diabetes
Gholamreza Asadikaram et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
Feng Tian et al.
BIOSCIENCE REPORTS (2018)
Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Yaron Rotman et al.
GUT (2017)
NAFLD and diabetes mellitus
Herbert Tilg et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Insulin action and resistance in obesity and type 2 diabetes
Michael P. Czech
NATURE MEDICINE (2017)
Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
Wenhuan Feng et al.
JOURNAL OF DIABETES (2017)
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck et al.
CIRCULATION (2017)
iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy
Lydia Lynch et al.
CELL METABOLISM (2016)
GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1
Fen Xu et al.
DIABETOLOGIA (2016)
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions
Kenneth Cusi
DIABETOLOGIA (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease
Claudia P. Oliveira et al.
JOURNAL OF DIABETES RESEARCH (2016)
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
Paola Portillo-Sanchez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
NAFLD incidence and remission: Only a matter of weight gain and weight loss?
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2015)
Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
Ning Shao et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2014)
Identification of Direct and Indirect Social Network Effects in the Pathophysiology of Insulin Resistance in Obese Human Subjects
Christian H. C. A. Henning et al.
PLOS ONE (2014)
Vildagliptin more effectively achieves a composite endpoint of HbA1c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment
Giovanni Bader et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2013)
The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis
Nitika A. Gupta et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Daniel J. Cuthbertson et al.
PLOS ONE (2012)
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsboll et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Shani Ben-Shlomo et al.
JOURNAL OF HEPATOLOGY (2011)
GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
Shvetank Sharma et al.
PLOS ONE (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
The incretin system and its role in type 2 diabetes mellitus
Jens Juul Holst et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Insulin-associated weight gain in diabetes - causes, effects and coping strategies
David Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2007)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
XK Ding et al.
HEPATOLOGY (2006)
Nonalcoholic fatty liver disease: A clinical review
DA Sass et al.
DIGESTIVE DISEASES AND SCIENCES (2005)
Medical consequences of obesity
GA Bray
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
分享论文
